Carlsbad, Calif.-based GenMark produces molecular tests that can identify the presence of several different pathogens, including those that cause COVID-19, from a single sample.
Roche will pay $24.05 per share in an all-cash transaction. The deal is expected to close in 2021’s second quarter.
More articles on pharmacy:
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Sanofi launches trial for 2nd COVID-19 vaccine candidate
Gilead, Merck co-developing long-acting HIV treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.